Oculis Holding AG

# Signal Note: Perceptive Advisors Initiates Oculis Position Perceptive's $9.9M entry into Oculis suggests confidence in the Swiss biotech's clinical-stage ophthalmology pipeline, likely anchored on OCL01 (suprachoroidal CsA) for dry eye disease—a large, underserved market where the company has demonstrated tolerability in early studies. The timing likely reflects positioning ahead of upcoming Phase 2b readout or IND-enabling data that could validate the suprachoroidal delivery approach as differentiated versus existing topical therapies. Edelman's clinical-stage expertise indicates focus on robust efficacy/safety inflection points rather than speculative plays.